KYINNO Antibody Production Platform: Your Partner in High-Quality Antibody Development

Antibody Production Overview

kyinno-antibody-production-platform-antibody-sequence

At the KYINNO Antibody Production Platform, we are committed to the development and production of high-quality antibodies for early drug discovery and preclinical research. Leveraging our optimized mammalian cell expression system, we offer comprehensive antibody expression and production services based on HEK293/CHO cells. Beginning with antibody sequence information, we provide customers with a one-stop solution encompassing gene construction, expression, purification, quality testing, and delivery of antibodies with high purity and low endotoxin levels.

kyinno-antibody-production-platform-testing-instruments

Our antibody expression utilizes a mammalian cell expression system, employing both transient small-scale expression and stable transfection to establish large-scale expression cell lines. The transient transfection system includes Expi-CHOS, Expi-293F, and the corresponding FUT8 knockout system, which effectively enhances antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Additionally, the stable transfection cell line expression system employs CHOK1 cells in conjunction with the GS knockout system and GS-FUT8 double knockout system. These expression systems are carefully chosen to ensure optimal product quality and yield.

Our antibody production platform is equipped with comprehensive hardware, including bioreactors, five AKTA systems, and a range of quality testing instruments such as Fortebio, flow cytometers, HPLC, CE/SDS, and LC/MS.

We offer a comprehensive array of services, from antibody production to quality testing. Furthermore, the buffer stored in the product can be customized to meet specific formulation requirements.

The KYINNO Antibody Production Platform provides an all-encompassing service, starting with gene construction and expression based on antibody sequence information. Our efficient and rapid recombinant antibody expression services involve the transfer of CHO/HEK293 cells, enabling the delivery of purified antibodies in as little as 2 weeks, all while meeting high yield and concentration specifications tailored to your downstream applications.

kyinno-antibody-production-platform-timeline

We offer a comprehensive array of services, from antibody production to quality testing. Furthermore, the buffer stored in the product can be customized to meet specific formulation requirements.

The KYINNO Antibody Production Platform provides an all-encompassing service, starting with gene construction and expression based on antibody sequence information. Our efficient and rapid recombinant antibody expression services involve the transfer of CHO/HEK293 cells, enabling the delivery of purified antibodies in as little as 2 weeks, all while meeting high yield and concentration specifications tailored to your downstream applications.

kyinno antibody production quality control system

With a stringent quality control system in place, KYINNO has amassed extensive successful experience in large-scale antibody production. Our products undergo rigorous testing, including molecular weight analysis, purity assessment, stability analysis, affinity and bioactivity verification, as well as functional and in vivo assays. We possess the capability to optimize culture and production programs to fulfill large-scale production demands, offering antibody production ranging from milligrams to grams, all compliant with the <0.5EU/mg endotoxin standard.

Our current inventory boasts a wide selection of 100 Benchmark antibodies, encompassing over 20 human IgG isotypes with Fc modifications, along with control antibodies targeting various antigens. Rest assured, each of these antibodies has undergone thorough quality control checks.

kyinno-benchmark-antibodies

In addition to our standard services, we offer specialized assistance in constructing antibody expression stable transfection cell lines. This process involves gene synthesis, cell transfection, monoclonal screening, rigorous quality assessment, and the ultimate delivery of qualified antibody expression stable transfection cell lines.

Remarkably, the KYINNO Antibody Production Platform has successfully constructed stable transfection cell lines for over 20 antibodies.

kyinno-antibody-production-stable-transfection-cell lines

All Antibody Discovery Services

Utilizing advanced biotechnology, our engineered bispecific antibodies bind two distinct targets. This innovation has the potential to revolutionize therapeutic strategies, heighten specificity, expand treatment options, and pave the way for future medical advancements.

Using antibodies with high specificity, Membrane Protein Antibody Discovery MPS AB5000 guarantee precise binding targets for CAR-T cells and biologics. This platform is foundational to therapeutic success and patient outcomes. Promoting next-generation healthcare solutions.

ai drug discovery service

AI Drug Discovery leverages advanced algorithms to revolutionize therapeutic antibody development by streamlining the traditionally cumbersome process.  Our AI-driven neural networks identify precise relationships between antibody and antigen structures, enabling the virtual generation of innovative antibody drugs.

FAQs About Our Customized Antibody Production Service

What is the difference between antibody discovery and antibody production at KYINNO?

  1. Antibody Discovery (or “Custom Antibody Service”) involves generating novel antibody sequences against specific targets.
  2. Antibody Production (KYINNO’s focus) involves taking an existing or discovered antibody sequence and scaling it up—expressing, purifying, and delivering high-quality recombinant antibodies in the required quantities.
  1. We primarily use mammalian cell expression systems, including HEK293 (e.g., Expi293) and CHO (e.g., ExpiCHO and CHOK1) cells.
  2. Depending on your needs, we can employ FUT8 knockout systems for enhanced ADCC and GS knockout systems (including GS-FUT8 double knockout) for optimized yields and product quality.
  1. Yes. Our platform supports milligram-scale production for early R&D phases and gram-scale production for preclinical applications. This flexibility ensures seamless scalability as your project moves forward.
  1. Production timelines vary based on project scope. For small-scale transient expression, we can deliver purified antibodies in as few as 2 weeks. For more extensive projects or stable cell line generation, timelines may be longer.
  1. We have a stringent, multi-step QC workflow that includes:
    1. -Purity assessment via SDS-PAGE and SEC-HPLC
    2. – Molecular weight confirmation via LC-MS/MS.
    3. – Stability analysis.
    4. – Affinity and bioactivity validation (e.g., Fortebio, Biacore and flow cytometry).
    5. – Endotoxin testing (<0.5 EU/mg).
    6. – In vivo functional assessments when necessary.
  1. Absolutely. We offer customizable buffer formulations to accommodate your unique downstream application needs, whether it’s for further development, assay work, or preclinical studies.
  1. Yes. Beyond transient expression, KYINNO can build stable transfection cell lines, which involves gene synthesis, cell transfection, monoclonal screening, and thorough QC to ensure reliable, long-term antibody expression.
  1. We adhere to a strict endotoxin standard of <0.5 EU/mg, making our antibodies suitable for in vivo experiments and advanced drug development applications.
  1. In addition to manufacturing services, we also provide:
    1. Custom isotype switching and Fc modifications.
    2. Large-scale production (milligrams to grams).
    3. Assistance with technology transfer for your in-house production.
    4. Access to our inventory of 100 “Benchmark” antibodies with diverse Fc modifications.
  1. Simply reach out via our contact details or online inquiry form. Provide us with your antibody sequence information and project requirements. Our technical experts will work with you to develop a customized production plan.